FDA advisers agree maternal RSV vaccine protects infants, but are divided on its safety | Science
A committee of advisers to the U.S. Food and Drug Administration (FDA) yesterday voted unanimously that a vaccine from Pfizer, given as an injection during pregnancy, is efficacious at protecting infants from severe respiratory syncytial virus (RSV) disease during the first 6 months of life. If approved by the agency, the vaccine would be a major advance against a disease that is the leading cause of hospitalization of U.S. infants. But troubled by side effect…